These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19373237)

  • 1. Administration time difference of candesartin effect on albuminuria in type 2 diabetic patients.
    Shimizu H; Uehara Y; Ohsaki A; Okada S; Mori M
    Hypertens Res; 2009 Jun; 32(6):527-8. PubMed ID: 19373237
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    Estacio RO; Coll JR; Tran ZV; Schrier RW
    Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease--a dose-response relationship study.
    Saha SA; LaSalle BK; Clifton GD; Short RA; Tuttle KR
    Am J Ther; 2010; 17(6):553-8. PubMed ID: 19829095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
    Fogari R; Corradi L; Zoppi A; Lazzari P; Mugellini A; Preti P; Rinaldi A
    Am J Hypertens; 2007 Oct; 20(10):1092-6. PubMed ID: 17903693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
    Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
    J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
    MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035422
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin receptor blockers in the prevention of atrial fibrillation recurrence: need for a definitive trial.
    Celik T; Iyisoy A
    Int J Cardiol; 2008 Jul; 127(2):276-7; author reply 278-9. PubMed ID: 17692408
    [No Abstract]   [Full Text] [Related]  

  • 10. Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
    Chatzikyrkou C; Menne J
    Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1087-92. PubMed ID: 23098143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
    Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney disease in diabetology: lessons from 2008.
    Schernthaner G
    Nephrol Dial Transplant; 2009 Feb; 24(2):396-9. PubMed ID: 19144896
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.
    García Donaire JA; Ruilope LM
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S22-30. PubMed ID: 17339065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
    Ikeda H; Hamamoto Y; Honjo S; Nabe K; Wada Y; Koshiyama H
    Diabetes Res Clin Pract; 2009 Jan; 83(1):117-8. PubMed ID: 19062123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
    Ingelfinger JR
    N Engl J Med; 2011 Mar; 364(10):970-1. PubMed ID: 21388316
    [No Abstract]   [Full Text] [Related]  

  • 19. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].
    Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
    MMW Fortschr Med; 2008 Feb; 150(6):40. PubMed ID: 18323344
    [No Abstract]   [Full Text] [Related]  

  • 20. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.